Attached files
| file | filename |
|---|---|
| EX-10.35 - EX-10.35 - ImmunityBio, Inc. | nk-ex1035_433.htm |
| EX-32.2 - EX-32.2 - ImmunityBio, Inc. | nk-ex322_11.htm |
| EX-32.1 - EX-32.1 - ImmunityBio, Inc. | nk-ex321_9.htm |
| EX-31.2 - EX-31.2 - ImmunityBio, Inc. | nk-ex312_6.htm |
| EX-31.1 - EX-31.1 - ImmunityBio, Inc. | nk-ex311_8.htm |
| EX-21.1 - EX-21.1 - ImmunityBio, Inc. | nk-ex211_10.htm |
| 10-K - 10-K - ImmunityBio, Inc. | nk-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-3 No. 333-233434) of NantKwest, Inc. for the registration of common stock, preferred stock, warrants, debt securities and units, |
|
|
(2) |
Registration Statement (Form S-4 No. 333-252232) of NantKwest, Inc. for the registration of common stock to be issued in connection with the merger with ImmunityBio, Inc., |
|
|
(3) |
Registration Statement (Form S-8 No. 333-205942) pertaining to the 2014 Equity Incentive Plan and 2015 Equity Incentive Plan, |
|
|
(4) |
Registration Statement (Form S-8 No.333-233082) pertaining to the 2015 Equity Incentive Plan as Amended and Restated, and |
|
|
(5) |
Registration Statement (Form S-8 No. 333-243725) pertaining to the 2015 Equity Incentive Plan as Amended and Restated; |
of our report dated March 4, 2021, with respect to the consolidated financial statements of NantKwest, Inc. included in this Annual Report (Form 10-K) of NantKwest, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Los Angeles, California
March 4, 2021